Phase II Study of Everolimus in Patients With Metastatic Colorectal Adenocarcinoma Previously Treated With Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

PURPOSE: Dysregulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is seen in 40–60% of colorectal cancer (CRC) patients. Everolimus, an oral inhibitor of mTOR, demonstrated efficacy in metastatic CRC (mCRC) patients in phase I studies. EXPERIMENTAL D...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ng, Kimmie, Tabernero, Josep, Hwang, Jimmy, Bajetta, Emilio, Sharma, Sunil, Del Prete, Salvatore A., Arrowsmith, Edward R., Ryan, David P., Sedova, Michaela, Jin, Jin, Malek, Kamel, Fuchs, Charles S.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3725595/
https://ncbi.nlm.nih.gov/pubmed/23743569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0027
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items